title: [Pain sensitivity changes in schizophrenic patients and animal models--Part II].
abstract: Diminished pain sensitivity in schizophrenic patients has been reported for more than 50 years, however little is known about the substrate and the basic mechanisms underlying altered pain sensitivity in this disease, therefore, relevant animal models are of decisive importance in the study of psychiatric diseases. The authors report a review consisting of two parts focusing on pain sensitivity changes in patients and in different animal models which proved the eligibility as schizophrenia models and pain sensitivities have also been determined. The second part of this article analyzed the results regarding knock out mice as schizophrenia models. These data proved that several genes have significant role in the pathomechanism of schizophrenia; therefore deficiency in one gene does not produce animals showing all signs of this disease. As regards the pain sensitivity changes, only a few data are available with controversial results. Data originated from complex chronic animal models indicate that they might be more adequate methods for studying the mechanisms of schizophrenia including the pain-sensitivity changes.
authors: Szegedi Tudományegyetem, Altalános Orvostudom6nyi Kar, Elettani Intézet, Szeged.
authors: Gábor
authors: G
authors: Tuboly
authors: Gyöngyi
authors: G
authors: Horváth
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000008:administration & dosage / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D018377:Neurotransmitter Agents / Q000235:genetics / Q000378:metabolism*; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D010146:Pain / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D017288:Pain Threshold; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D043643:Receptor, Muscarinic M1 / Q000378:metabolism; D043642:Receptor, Muscarinic M5 / Q000378:metabolism; D011973:Receptors, LDL / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism / Q000503:physiopathology*; D012934:Social Isolation; D050916:TRPV Cation Channels / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D002186:Cannabinoids; D004268:DNA-Binding Proteins; C539882:NR4A2 protein, human; D018377:Neurotransmitter Agents; C539883:Nr4a2 protein, mouse; C539884:Nr4a2 protein, rat; D057126:Nuclear Receptor Subfamily 4, Group A, Member 2; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D043643:Receptor, Muscarinic M1; D043642:Receptor, Muscarinic M5; D011973:Receptors, LDL; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; C493921:TRPV1 protein, mouse; D014157:Transcription Factors; C036053:VLDL receptor